Daklinza licence extension
Daklinza (daclatasvir; Bristol Myers Squibb), used in combination with other drugs to treat hepatitis C, has been approved for extended use for patients co-infected with HIV and also post liver transplantation by the European Medicines Agency.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20200646
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com